| アブストラクト | Background and aims: Effective glycemic control is the cornerstone of successful type 2 diabetes management. However, many patients fail to reach glycemic control targets, and therapeutic inertia (failure to intensify therapy to address poor glycemic control in a timely manner) has been widely reported. The aim of the present study was to evaluate the economic burden associated with diabetes-related complications due to poor glycemic control for patients with type 2 diabetes in the UK.Methods: A validated long-term model of type 2 diabetes (IQVIA CORE Diabetes Model) was used to project cost outcomes for a UK population with type 2 diabetes, based on data from The Health Improvement Network primary care database, at different levels of glycemic control. Costs associated with diabetes-related complications were accounted in 2017 Pounds Sterling (GBP). Complication costs were estimated for populations achieving different glycated hemoglobin (HbA1c) targets, in a number of delayed treatment intensification scenarios, and across a range of time horizons.Results: For patients with an HbA1c level of 8.2% (66 mmol/mol), 7 years in poor control could increase mean costs associated with diabetes-related complications by over GBP 690 per patient and lead to costs of over GBP 1,500 in lost workplace productivity compared with achieving good glycemic control (HbA1c 7.0%, 53 mmol/mol) over a 10-year time horizon. Based on published estimates of the proportion of type 2 diabetes patients failing to meet glycemic targets in the UK, this corresponds to an additional economic burden of approximately GBP 2,600 million (complication costs plus lost productivity costs).Conclusions: The economic burden of poor glycemic control in type 2 diabetes in the UK is substantial. Efforts to avoid therapeutic inertia could substantially reduce diabetes-related complication costs even in the short-term. |
|---|
| ジャーナル名 | Journal of medical economics |
|---|
| Pubmed追加日 | 2019/7/18 |
|---|
| 投稿者 | Bain, Stephen C; Bekker Hansen, Brian; Hunt, Barnaby; Chubb, Barrie; Valentine, William J |
|---|
| 組織名 | Diabetes Research Unit Cyrmu, Swansea University Medical School, Swansea, UK.;Global Patient Access, Novo Nordisk A/S, Soborg, Denmark.;Health Economics, Ossian Health Economics and Communications, Basel, Switzerland.;External Affairs, Novo Nordisk Ltd, Gatwick, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31311364/ |
|---|
